CD274 and esophageal squamous cell carcinoma: At the base-case WTP threshold and current price, the CEAC demonstrated that the probability of nivolumab combination therapy strategies being cost-effective was 0% in overall and PD-L1-positive ESCC patients (Figures 5, 6).